Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 13/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.68 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.57 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.50 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203058 | 0.97 | L3MBTL3 (0.73) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL25675681 | 0.95 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL12744643 | 0.87 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL14329223 | 0.87 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL23328251 | 0.87 | KDM2B (0.53) | L3MBTL3L3MBTL1MBTD1HRH3MEN1 | |
| SCHEMBL12666610 | 0.86 | KMT2A (0.56) | L3MBTL3L3MBTL1HRH3MEN1KMT2A | |
| SCHEMBL18308985 | 0.86 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL12125869 | 0.85 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1HRH3MEN1KMT2A | |
| SCHEMBL10202402 | 0.85 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1HRH3MEN1KMT2A | |
| SCHEMBL12125866 | 0.85 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2021254389-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | 微境生物医药科技(上海)有限公司 | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | WEE1, WEE2, PEAK1 | L3MBTL3 4848/4885L3MBTL1 4572/4885MBTD1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.